For Dr. Scott LaBorwit, adding OMIDRIA (phenylephrine and ketorolac intraocular solution) 1% / 0.3% has redefined what’s possible in drop-free cataract surgery.
The only FDA-approved intracameral NSAID, OMIDRIA reduces intra- and postoperative inflammation, supporting faster, more comfortable cases.
Dr. LaBorwit shares how adding OMIDRIA to his dropless cataract surgery regimen has transformed his workflow, reduced case times, and improved both patient and staff satisfaction.
Key data mentioned:
—Donnenfeld et al.: Vitreous ketorolac concentration >2,500 ng/mL with OMIDRIA vs 3 ng/mL with topical drops (≈800× higher).
—Supports inflammation control and reduces CME risk after surgery.
Learn more at www.omidria.com.
The experiences shared are based on one surgeon’s practice and may not be typical. OMIDRIA is not approved to replace postoperative therapies or for a drop-free regimen. Claims about efficiency and outcomes are anecdotal and do not demonstrate superiority. Refer to the OMIDRIA Full Prescribing Information for important details; content is for US HCPs only. Products discussed may not be approved in all jurisdictions, including Singapore.
US-OM-2500070 12/25
